Literature DB >> 22215397

[Prevalence of chronic kidney disease in subjects consulting in urban primary care clinics].

Carlos Zúñiga S M1, Hans Müller O, Maritza Flores O.   

Abstract

BACKGROUND: Chronic kidney disease (CKD) is a major worldwide public health problem and is associated with increased risk of cardiovascular disease and death. AIM: To assess CKD prevalence in urban Primary Care Services (PCS) of Concepcion, Chile.
MATERIAL AND METHODS: The clinical records of 27.894 adults aged 55 ± 18 years (66% females), consulting in outpatient clinics and in whom serum creatinine was measured, with or without assessment of urine albumin levels, were reviewed. The glomerular filtration rate (eGFR) was estimated using the Modification of Diet in Renal Disease (MDRD)-4 equation. CKD was defined as an eGFR < 60 ml/min/1.73 m2 and classified according to the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NFK-KDOQI) guidelines.
RESULTS: Mean eGFR was 77.1 ± 16.3 ml/min/1.73 m2. Twelve percent of subjects had CKD (women, 14.5% and men 7,4%, p < 0,05). The prevalence of stages 3, 4 and 5 of CKD were 11.6, 0.3 and 0.2 % respectively. eGFR was negatively correlated with age ( r = -0,54, p < 0,05). Among patients with an eGFR < 60 ml/min/1.73 m2, 96.3% had eGFR 30-59, 2.3% 15-29 and 1.4 % < of 15. Seventy nine percent were women. 75.1% were aged 65 years or more, 26.8% had a serum creatinine equal or less than 1.0 mg/dL and 40.5% had microalbuminuria. Only 1% of outpatients ascribed to Cardiovascular or Diabetes Programs had the diagnosis of CKD registered. Independent risk predictors of CKD were age > 60 years, female sex and microalbuminuria.
CONCLUSIONS: This study showed a high prevalence of CKD in ambulatory patients, mainly among women and older people. The low level of diagnosis of CKD in cardiovascular and diabetes programs is of concern.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22215397     DOI: /S0034-98872011000900010

Source DB:  PubMed          Journal:  Rev Med Chil        ISSN: 0034-9887            Impact factor:   0.553


  6 in total

1.  Combined application of eGFR and albuminuria for the precise diagnosis of stage 2 and 3a CKD in the elderly.

Authors:  Conghui Liu; Haiping Chen; Cuiyun Liu; Chen Fu; Hui Zhang; Huayu Yang; Peng Wang; Fan Wang; Shujun Chen; Qing Ma
Journal:  J Nephrol       Date:  2014-03-08       Impact factor: 3.902

2.  Effect of altitude on mortality of end-stage renal disease patients on hemodialysis in Peru.

Authors:  Katia Bravo-Jaimes; Viky Y Loescher; Carlos Canelo-Aybar; Jose Rojas-Camayo; Christian R Mejia; Sandra Schult; Ruben Nieto; Kyra Singh; Susan Messing; Juana Hinostroza
Journal:  Clin Kidney J       Date:  2020-06-22

Review 3.  Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis.

Authors:  Nathan R Hill; Samuel T Fatoba; Jason L Oke; Jennifer A Hirst; Christopher A O'Callaghan; Daniel S Lasserson; F D Richard Hobbs
Journal:  PLoS One       Date:  2016-07-06       Impact factor: 3.240

4.  The epidemiology of renal replacement therapy in two different parts of the world: the Latin American Dialysis and Transplant Registry versus the European Renal Association-European Dialysis and Transplant Association Registry.

Authors:  Rosario Luxardo; Anneke Kramer; Maria Carlota González-Bedat; Ziad A Massy; Kitty J Jager; Guillermo Rosa-Diez; Marlies Noordzij
Journal:  Rev Panam Salud Publica       Date:  2018-09-07

5.  Prevalence of chronic kidney disease in Peruvian primary care setting.

Authors:  Percy Herrera-Añazco; Alvaro Taype-Rondan; María Lazo-Porras; E Alberto Quintanilla; Victor Manuel Ortiz-Soriano; Adrian V Hernandez
Journal:  BMC Nephrol       Date:  2017-07-19       Impact factor: 2.388

6.  Wholegrain Consumption and Risk Factors for Cardiorenal Metabolic Diseases in Chile: A Cross-Sectional Analysis of 2016-2017 Health National Survey.

Authors:  Fabian Lanuza; Raul Zamora-Ros; Nicole Hidalgo-Liberona; Cristina Andrés-Lacueva; Tomás Meroño
Journal:  Nutrients       Date:  2020-09-14       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.